Efficacy and Safety of 1-month Postpartum Zidovudine-didanosine to Prevent HIV-resistance Mutations After Intrapartum Single-dose Nevirapine

Background: Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks postpartum risks selection of resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs). We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations.

Methods: HIV-infected pregnant women in the PHPT-4 cohort with CD4 cell counts >250 cells/mm3 received antepartum zidovudine from the third trimester until delivery, sdNVP during labor, and a 1-month zidovudine-didanosine course after delivery. These women were matched on the basis of baseline HIV load, CD4 cell count, and duration of antepartum zidovudine to women who received sdNVP in the PHPT-2 trial (control subjects). Consensus sequencing and the more sensitive oligonucleotide ligation assay were performed on samples obtained on postpartum days 7-10, 37-45, and 120 (if the HIV load was >500 copies/mL) to detect K103N/Y181C/G190A mutations.

Results: The 222 PHPT-4 subjects did not differ from matched control subjects in baseline characteristics except for age. The combined group median CD4 cell count was 421 cells/mm3 (interquartile range [IQR], 322-549 cells/mm3), the median HIV load was 3.45 log10 copies/mL (IQR, 2.79-4.00 log10 copies/mL), and the median duration of zidovudine prophylaxis was 10.4 weeks (IQR, 9.1-11.4 weeks). Using consensus sequencing, major NNRTI resistance mutations were detected after delivery in 0% of PHPT-4 subjects and 10.4% of PHPT-2 controls. The oligonucleotide ligation assay detected resistance in 1.8% of PHPT-4 subjects and 18.9% of controls. Major NNRTI resistance mutations were detected by either method in 1.8% of PHPT-4 subjects and 20.7% of controls (P < .001).

Conclusions: A 1-month postpartum course of zidovudine plus didanosine prevented the selection of the vast majority of NNRTI resistance mutations.

Citing Articles

Essential components of postnatal care - a systematic literature review and development of signal functions to guide monitoring and evaluation.

McCauley H, Lowe K, Furtado N, Mangiaterra V, van den Broek N BMC Pregnancy Childbirth. 2022; 22(1):448.

PMID: 35643432 PMC: 9148465. DOI: 10.1186/s12884-022-04752-6.

Zika Virus Immunoglobulin G Seroprevalence among Young Adults Living with HIV or without HIV in Thailand from 1997 to 2017.

Choyrum S, Wangsaeng N, Nechba A, Salvadori N, Saisom R, Achalapong J Viruses. 2022; 14(2).

PMID: 35215960 PMC: 8878279. DOI: 10.3390/v14020368.

Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015.

Ngo-Giang-Huong N, Leroi C, Fusco D, Cressey T, Wangsaeng N, Salvadori N Viruses. 2021; 13(8).

PMID: 34452289 PMC: 8402824. DOI: 10.3390/v13081423.

Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.

Lallemant M, Amzal B, Sripan P, Urien S, Cressey T, Ngo-Giang-Huong N J Acquir Immune Defic Syndr. 2020; 84(3):313-322.

PMID: 32205720 PMC: 9741956. DOI: 10.1097/QAI.0000000000002350.

Comparison of anti-retroviral therapy treatment strategies in prevention of mother-to-child transmission in a teaching hospital in Ethiopia.

Kumela K, Amenu D, Chelkeba L Pharm Pract (Granada). 2015; 13(2):539.

PMID: 26131041 PMC: 4482841. DOI: 10.18549/pharmpract.2015.02.539.

References

Cressey T, Leenasirimakul P, Jourdain G, Tawon Y, Sukrakanchana P, Lallemant M . Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 42(3):387-9. DOI: 10.1097/01.qai.0000221685.90681.1b. View

Eshleman S, Hoover D, Chen S, Hudelson S, Guay L, Mwatha A . Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005; 192(1):30-6. DOI: 10.1086/430764. View

Chaix M, Ekouevi D, Rouet F, Tonwe-Gold B, Viho I, Bequet L . Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis. 2006; 193(4):482-7. DOI: 10.1086/499966. View

Beck I, Crowell C, Kittoe R, Bredell H, Machaba M, Willamson C . Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008; 48(4):418-27. PMC: 2583356. DOI: 10.1097/QAI.0b013e31817ed7d7. View

Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P . Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004; 351(3):229-40. DOI: 10.1056/NEJMoa041305. View

Lim S, Wai C, Rajnakova A, Kajiji T, Guan R . Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002; 51(4):597-9. PMC: 1773395. DOI: 10.1136/gut.51.4.597. View

Beck I, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E . Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol. 2002; 40(4):1413-9. PMC: 140364. DOI: 10.1128/JCM.40.4.1413-1419.2002. View

Lallemant M, Jourdain G, Le Coeur S, Mary J, Ngo-Giang-Huong N, Koetsawang S . Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351(3):217-28. DOI: 10.1056/NEJMoa033500. View

Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D . Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008; 16(1):62-8. DOI: 10.1007/s11750-007-0034-z. View

10.

Warszawski J, Tubiana R, Chenadec J, Blanche S, Teglas J, Dollfus C . Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2007; 22(2):289-99. DOI: 10.1097/QAD.0b013e3282f3d63c. View

11.

Lockman S, Shapiro R, Smeaton L, Wester C, Thior I, Stevens L . Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356(2):135-47. DOI: 10.1056/NEJMoa062876. View

12.

Arrive E, Newell M, Ekouevi D, Chaix M, Thiebaut R, Masquelier B . Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007; 36(5):1009-21. DOI: 10.1093/ije/dym104. View

13.

Arrive E, Chaix M, Nerrienet E, Blanche S, Rouzioux C, Coffie P . Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS. 2009; 23(7):825-33. DOI: 10.1097/QAD.0b013e32832949d5. View

14.

Cressey T, Jourdain G, Lallemant M, Kunkeaw S, Jackson J, Musoke P . Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005; 38(3):283-8. View

15.

Zhang J, Wang X, Huang Y, Yin Y, Guan S, Xu Y . Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy. J Med Virol. 2006; 78(3):324-8. DOI: 10.1002/jmv.20543. View

16.

. Abstracts presented at the XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 10-14 June 2003, Los Cabos, Mexico. Antivir Ther. 2004; 8(3):S1-170. View

17.

Wiwanitkit V . An overview of hepatitis B serology screening check-up program among Thai workers. Viral Immunol. 2003; 15(4):647-9. DOI: 10.1089/088282402320914575. View

18.

Altfeld M, Rockstroh J, Addo M, Kupfer B, Pult I, Will H . Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998; 29(2):306-9. DOI: 10.1016/s0168-8278(98)80017-2. View

19.

Eshleman S, Guay L, Mwatha A, Brown E, Cunningham S, Musoke P . Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr. 2004; 35(2):126-30. DOI: 10.1097/00126334-200402010-00004. View

20.

Dorenbaum A, Cunningham C, Gelber R, Culnane M, Mofenson L, Britto P . Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002; 288(2):189-98. DOI: 10.1001/jama.288.2.189. View